Clinical-stage biotechnology company
Appears in 1 story
Targeting BLA submission by end-September 2026; proposed $150 million equity offering on June 22 to fund commercialization
Hidradenitis suppurativa causes painful, recurring abscesses in the skin folds of about 1 in 100 people. For most of the past decade, one drug controlled it well enough to win U.S. approval.
Updated Jun 23
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
